

## Electronic Supporting Information

### **L-Proline-catalysed synthesis of chromeno[2,3-*b*]chromene from 4-hydroxy-2*H*-chromene-2-thione and some of their anti-proliferative study**

Arnab Mandal,<sup>a</sup> Satyajit Singh,<sup>a</sup> Arisha Arora,<sup>b</sup> Sujisha S. Nambiar,<sup>b</sup> Siddhartha S. Ghosh,<sup>b</sup> Abu Taleb Khan\*<sup>a</sup>

<sup>a</sup> Department of Chemistry, Indian Institute of Technology Guwahati, Guwahati-781039, Assam, India.

E-mail: atk@iitg.ac.in

<sup>b</sup> Department of Bioscience and Bioengineering, Indian Institute of Technology Guwahati, Guwahati-781039, Assam, India.

<b>Content</b>	<b>Page No.</b>
Target prediction of compound 4a using Super PRED	S2
Protein expression analysis using the UALCAN database	S2
Gene enrichment analysis	S2
Molecular docking	S2
Cell Lines and Culture Condition	S2
Cell viability assay	S3
Reactive Oxygen Species Detection Assay	S3
Live-dead cell imaging	S3
Crystallographic parameters for 4d and 4m	S4
Gene expression analysis of predicted targets	S5
gene enrichment analysis of CTSD	S5
2D interaction profiles of compounds with CTSD	S6-S8
Molecular docking analysis of compounds	S8-S10
NMR and HRMS spectra of all the compounds	S11-S102
HRMS spectra of reaction intermediates	S103-S104
References	S106

### **Target prediction of compound 4a using Super PRED**

SuperPred (<https://prediction.charite.de/index.php>) is a web-based tool for predicting potential targets of small-molecule compounds based on the similarity of the compounds to known bioactive compounds and the likelihood of the compounds interacting with various proteins. The SMILES of compound 4a were submitted to Super PRED. The highest-ranked protein targets were screened for further analysis.

### **Protein expression analysis using the UALCAN database**

THE PREDICTED PROTEINS WERE UPLOADED using UALCAN (<https://ualcan.path.uab.edu/>), and expression analysis on breast cancer was performed.<sup>1</sup> Box plots were created to visually represent the expression levels of these proteins in comparison to normal tissues, and statistical significance was assessed using UALCAN's integrated tools.

### **Gene enrichment analysis**

Gene enrichment analysis was performed on CTSD using the Enrichr web tool (<https://maayanlab.cloud/Enrichr/>) to identify biological pathways and functional annotations associated with CTSD. The significance levels and p-values were computed to assess the enrichment results.

### **Molecular docking**

CTSD (PDB ID: 4OD9) crystal structure was obtained from the Protein Data Bank (<https://www.rcsb.org/>) and used as the receptor for molecular docking. The Swiss PDB viewer was used to perform protein-energy minimization. The protein and ligand structures were prepared with Autodock tools (MGLTools 1.5.7), and blind docking was performed for all compounds, as well as site-specific docking for the control inhibitor by specifying the region of the protein where the ligand is expected to bind using a grid box that encloses the search space. The docking simulation was run, and the AutoDock Vina search algorithm was used to generate potential binding poses for the ligand within the defined search space.<sup>2</sup> The docking simulation results are analysed to determine the ligand's best binding pose and binding affinity to the protein. Discovery Studio generated the 2D interaction profile of protein-ligand complexes.

### **Cell Lines and Culture Condition**

Breast cancer cell line MCF7 was purchased from the National Centre of Cell Science (NCCS) cell repository in Pune, India. It was cultured in Dulbecco's Modified Eagle's medium-high glucose supplemented with l-glutamine and sodium pyruvate (Sigma Aldrich). Additionally, sodium bicarbonate, 10% fetal bovine serum (FBS) (Gibco, USA), 100 units/mL and 100 µg/mL penicillin and streptomycin, respectively (Thermo Fisher Scientific, USA) were added. The cells were maintained under humidified air conditions comprising 5% CO<sub>2</sub> at 37°C.

### Cell viability assay

To assess the effect of the selected compounds on the viability of breast cancer cells, MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrasodium bromide) cell viability assay was performed (ref 3). This assay's principle is based on converting coloured tetrazolium dye to purple-coloured insoluble formazan crystals by the metabolically active living cells, measured by the change in absorbance.<sup>3</sup> Standard protocol for MTT was used to measure cell viability. Briefly,  $3 \times 10^3$  cells/well were seeded in a 96-well plate (ThermoScientific, India) and grown for 24 hours at 37°C under 5% CO<sub>2</sub>. Next, cells were treated with increasing concentrations of the compounds and incubated for 48 hours at 37°C under 5% CO<sub>2</sub>. Following incubation, MTT solution was added to each well and incubated for 1.50 hours. The formazan crystals (MTT metabolic product) thus formed were dissolved in dimethyl sulfoxide (DMSO), and the absorbance was taken using a microplate reader (Infinite 200 PRO, Tecan, Germany) at 570 nm along with a reference wavelength at 630 nm. For the calculation, taking the cell viability of the untreated cells as 100%, the compounds' 50% inhibitory concentration (IC<sub>50</sub>) was determined from the *dose*-response curve using the GraphPad Prism. The formula used for the cell viability (%) determination is as follows:

$$\% \text{ Cell viability} = \frac{[(Abs_{570} - Abs_{630}) \text{ treated cells}]}{[(Abs_{570} - Abs_{630}) \text{ control cells}]} \times 100$$

### Reactive Oxygen Species Detection Assay







The level of reactive oxygen species (ROS) has been known to affect various aspects of tumour development, progression, and apoptosis. For the study, cellular ROS generation has been assessed using the DCFDA (2',7'-dichlorofluorescein diacetate) dye. DCFDA is a non-fluorescent, ROS-sensitive dye and the precursor of DCF (2',7'-dichlorofluorescein). On entering the cell, DCFDA is oxidized to DCF in the presence of several cellular reactive oxygen species within the cells, and DCF could be monitored by an increase in fluorescence.<sup>4</sup> For the study, cells were treated with the compounds for 6h and incubated with 2µM DCFDA for 30 min. Following this, the cells were trypsinized, washed once with 1X PBS, and resuspended in PBS. The generation of ROS was identified by flow cytometry analysis in the FITC channel using the CytoFLEX (Beckman Coulter) flow cytometer.

### Live-dead cell imaging


For live-dead cell imaging, MCF-7 cells were treated with the parent compound 4a and the selected compounds 4d, 4l and 4p at their respective IC<sub>50</sub> concentration for 48h. Following treatment, cells were incubated for 30 mins with 2 µM calcein-AM and 4 µM PI. After the incubation, the live-dead populations were imaged using a ZOE Fluorescent Cell Imager fluorescence microscope (Bio-Rad).

**Table S1.** Crystallographic parameters for **4d** and **4m**.













	<b>4d</b>	<b>4m</b>
<b>CCDC No.</b>	2284128	2284121
<b>Empirical formula</b>	C <sub>24</sub> H <sub>19</sub> ClO <sub>4</sub>	C <sub>25</sub> H <sub>21</sub> ClO <sub>4</sub>
<b>Formula weight</b>	406.868	420.895
<b>Temperature/K</b>	296.00	298
<b>Crystal system</b>	monoclinic	triclinic
<b>Space group</b>	P2 <sub>1</sub> /c	P-1
<b>a/Å</b>	9.1059(15)	9.3610(7)
<b>b/Å</b>	21.916(4)	11.2049(8)
<b>c/Å</b>	10.1282(17)	11.6661(9)
<b>α/°</b>	90	103.780(3)
<b>β/°</b>	105.051(5)	93.986(3)
<b>γ/°</b>	90	114.062(2)
<b>Volume/Å<sup>3</sup></b>	1951.9(6)	1065.83(14)
<b>Z</b>	4	2
<b>ρ<sub>calc</sub>(g/cm<sup>3</sup>)</b>	1.385	1.311
<b>μ/mm<sup>-1</sup></b>	0.225	0.208
<b>F(000)</b>	849.1	440.6
<b>Radiation</b>	Mo Kα (λ = 0.71073)	Mo Kα (λ = 0.71073)
<b>2θ range for data collection/°</b>	3.72 to 52.46	4.16 to 51.34
<b>Index ranges</b>	-11 ≤ h ≤ 11, -26 ≤ k ≤ 27, -12 ≤ l ≤ 12	-11 ≤ h ≤ 11, -13 ≤ k ≤ 13, -14 ≤ l ≤ 14
<b>Reflections collected</b>	41936	25693
<b>Independent reflections</b>	3852	4032
<b>Data/restraints/parameters</b>	3852/0/264	4032/0/274
<b>Goodness-of-fit on F<sup>2</sup></b>	1.049	1.027
<b>Final R indexes [I ≥ 2σ (I)]</b>	R <sub>1</sub> = 0.0896, wR <sub>2</sub> = 0.2752	R <sub>1</sub> = 0.0538, wR <sub>2</sub> = 0.1478
<b>Final R indexes [all data]</b>	R <sub>1</sub> = 0.1056, wR <sub>2</sub> = 0.2848	R <sub>1</sub> = 0.0698, wR <sub>2</sub> = 0.1572
















**Fig. S1** Gene expression analysis of predicted targets.



**Fig. S2** gene enrichment analysis of CTSD.







**Fig. S3.** 2D interaction profiles of compounds with CTSD.

**Table S2.** Molecular docking analysis of compounds

Compound	Binding energy	No of H bonds	Interacting amino-acids in H bond	No of other bonds	Interacting amino-acids in the non-covalent interactions
4a	-7.7	1	SER315	13	PRO313, TYR205, ILE142, SER37, SER36, VAL144, ILE76, TYR78, HIS77, GLY79, ILE311, PRO312, PRO314
4b	-8.6	1	HIS77	13	ILE76, TYR78, SER36, GLY35, TYR205, ILE142, ARG141, ASN146, SER143, VAL144, ASP75
4c	-8.3	0		13	PRO314, PRO312, SER315, TYR205, ILE142, SER37, VAL144, SER36, ILE76, TYR78, HIS77, GLY79, ILE311
4d	-9.3	1	SER315	12	ILE311, PRO312, TYR78, TYR205, HIS77, ILE76, VAL144, SER36, GLY35, ILE142, ARG141, ARG202
4e	-8.1	0		15	PRO209, PRO208, PRO207, ILE206, GLY78, HIS76, TYR77, ILE75, SER35, ASN37, SER36, ILE37, VAL39, TYR100, SER210
4f	-8.5	0		16	ASP66, PRO67, ASP68, VAL162, LYS187, ASP11, LEU186, THR185, GLU182, TYR184, ASP183, ARG65
4g	-7.7	1	SER315	12	PRO314, PRO312, ILE311, HIS77, GLY79, TYR78, ILE76, VAL144, ILE142, SER36, SER37
4h	-7.9	1	SER315	12	PRO314, PRO312, ILE311, HIS77, GLY79, TYR78, ILE76, VAL144, ILE142, SER36, SER37, TYR205




4i	-8.6	1	SER315	11	TYR205, TYR78, GLY35, SER36, HIS77, VAL144, ILE76, ASP75, PRO312, ILE311, ILE142
4j	-8.3	2	GLN121, LYS120	18	ASP50, LEU49, LYS47, ALA175, ASP172, SER82, ASP174, ASP75, SER84, PRO122, LYS120
4k	-8.8	2	SER315	12	ARG202, ARG141, ILE142, VAL144, ILE76, GLY35, TYR78, SER36, HIS77, TYR205, PRO312, ILE311
<b>4l</b>	<b>-9.8</b>	1	SER315	14	ILE311, TYR205, PRO312, GLY35, ILE142, SER35, ILE76, HIS77, ASP75, VAL144, PRO314, ARG202, ARG141
4m	-8.0	1	SER315	10	ILE142, ASN38, VAL144, ILE76, SER37, SER36, TYR78, TYR205, PRO314, HIS77
4n	-8.6	0		13	ILE142, GLY79, TYR78, TYR205, ILE311, PRO312, SER315, ARG202, ARG141, HIS77, VAL144, ILE76, SER36
4o	-7.9	2	SER315, TYR205	10	PRO312, ILE311, VAL144, HIS77, TYR78, GLY35, SER36, ILE76, ILE142
<b>4p</b>	<b>-9.1</b>	1	LYS293	17	LYS293, VAL268, LEU292, THR291, GLU288, ARG171, ASP289, ASP172, PRO173, ASP174, SER295
4q	-8.1	0		16	GLY78, ILE206, PRO209, PRO207, PRO208, SER210, TYR100, ILE37, SER35, SER36, ASN37, ILE75, VAL39, TYR77, HIS76
4r	-7.7	0		17	VAL39, ILE75, ASN37, SER36, SER35, ILE37, TYR100, SER210, PRO209, PRO207, PRO208, ILE206, GLY78, TYR77, HIS76
4s	-7.8	2	HIS76	14	ILE206, GLY78, TYR100, ILE37, TYR77, ILE75, SER35, SER36, ASN37, VAL39, ASP74, ASN40, PRO207
4t	-7.8	1	SER210	13	PRO209, PRO207, PRO208, ILE206, HIS76, TYR77, GLY78, VAL39, ILE37, ILE75, SER35, SER36, TYR100
4u	-8.0	0		16	VAL39, TYR77, HIS76, GLY78, ILE206, PRO209, PRO207, PRO208, SER210, TYR100, ILE37, SER35, SER36, ASN37, ILE75
4v	-8.0	1	LYS187	17	LEU186, SER189, ASP68, ASP66, PRO67, ARG65, ASP183, GLU182, THR185, VAL162,
4w	-8.5	2	LYS120,SER82	17	LYS47, ASP50, GLN121, LEU49, LYS120, ASP172, SER84,ASP174, PRO122, HIS77, ASP75, ALA175,GLN176
4x	-8.6	1	SER315	11	ASP75, HIS77, VAL144, ILE76, ILE142, SER37, SER36, TYR205, ILE311, PRO312
4y	-8.8	0		15	VAL268, LYS293, ASP174, PRO173, ASP172, ASP289, GLU288, LEU292, THR291, ARG171, ASP12
4z	-8.1	1	SER210	12	PRO209, VAL39, ILE37, ILE75, SER36, SER35, HIS76, TYR77, ILE206, PRO207, PRO208
4aa	-8.3	0		14	PRO312, PRO313, PRO314,SER315, TYR205, ILE142, ILE76, VAL144, SER37, SER36, TYR78, HIS77, GLY79, ILE311
4ab	-7.8	1	TYR205	15	SER37, SER36, ASN38, ILE76, TYR78, VAL144,

					ILE142, HIS77, GLY79, PRO314, ILE311, PRO312, PRO313, SER315
Control - inhibitor(NAG)	-5.6	3	ASN145, THR72	6	ASN146, VAL147, VAL114, LEU87, ASN70


**<sup>1</sup>H NMR (600MHz, 1:1 CDCl<sub>3</sub> and D6-DMSO) spectrum of 4-hydroxy-6-methyl-2H-chromene-2-thione**

AM-TC-ME-1H.1.fid — 1H




**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (150MHz, 1:1 $\text{CDCl}_3$  and  $\text{D}_6$ -DMSO) spectrum of 4-hydroxy-6-methyl-2H-chromene-2-thione**

AM-TC-ME-13C.3.fid — 13C




**<sup>1</sup>H NMR (600MHz, 1:1CDCl<sub>3</sub> and D6-DMSO) spectrum of 4-hydroxy-6-methoxy-2H-chromene-2-thione**

AM-TC-OME-1H.1.fid — 1H



**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (150MHz, 1:1 $\text{CDCl}_3$  and D6-DMSO) spectrum of 4-hydroxy-6-methoxy-2H-chromene-2-thione**

AM-TC-OME-13C.3.fid — 13C




**<sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4a**

ATK-AM-03-78-1H.1.fid — ATK-AM-03-78-1H


8.09  
8.09  
8.08  
8.08  
7.65  
7.64  
7.63  
7.63  
7.63  
7.61  
7.61  
7.43  
7.41  
7.40  
7.37  
7.37  
7.36  
7.36  
7.35  
7.34  
7.34  
7.26  
7.26  
7.24  
7.22  
7.14  
7.13  
7.11  
5.16

2.62  
2.32  
2.28  
2.26  
2.23

1.15  
1.08




**4a**



S15

**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4a**


ATK-AM-03-78-13C.3.fid — ATK-AM-03-78-13C



S16




# HRMS spectrum of compound 4a




# <sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4b

ATK-AM-03-53-P2-1H.3.fid — ATK-AM-03-53-P2-1H




4b




**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4b**

ATK-AM-03-53-P2-13C.1.fid — ATK-AM-03-53-P2-13C




**$^{19}\text{F}$  NMR (471 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4b**

AM-03-53-19F.1.fid — AM-03-53-19F




## HRMS spectrum of compound 4b




**<sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4c**

AM-03-76-P2-1H.1.fid — AM-03-76-P2-1H




**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4c**

AM-03-76-P2-13C.3.fid — AM-03-76-P2-13C



S23



### HRMS spectrum of compound 4c






# <sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4d

ATK-AM-80-1H.1.fid — ATK-AM-80-1H





4d



S25


**$^{13}\text{C}$  { $^1\text{H}$ } NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4d**

AM-03-80-13C.12.fid — AM-03-80-13C





**4d**

### HRMS spectrum of compound 4d




# <sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4e

AM-03-88-P2-1H.1.fid — AM-03-88-P2-1H





4e



S28


**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4e**

AM-03-88-P2-13C.3.fid — AM-03-88-P2-13C




**4e**

# HRMS spectrum of compound 4e




**<sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4f**

AM-03-99-P2-1H.3.fid — AM-03-99-P2-1H




**4f**



S31

$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound **4f**


AM-03-99-P2-13C.1.fid — AM-03-99-P2-13C



S32



### HRMS spectrum of compound 4f



**<sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4g**


ATK-AM-77-1H.1.fid — ATK-AM-77-1H

8.07  
8.07  
8.06  
8.05  
7.68  
7.68  
7.67  
7.67  
7.66  
7.65  
7.65  
7.54  
7.53  
7.46  
7.44  
7.40  
7.39  
7.37  
7.26


— 5.17

— 2.64  
2.33  
2.30  
2.26  
2.22

— 1.16  
— 1.07




**4g**



S34


**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4g**

ATK-AM-77-13C.3.fid — ATK-AM-77-13C



S35

### HRMS spectrum of compound 4g




# <sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4h

AM-85-P2-1H.1.fid — AM-85-P2-1H


8.13  
8.10  
8.08  
8.08  
8.06  
8.06  
7.69  
7.69  
7.68  
7.67  
7.67  
7.66  
7.65  
7.60  
7.58  
7.47  
7.45  
7.41  
7.39  
7.37  
7.26  
— 5.24

— 2.65  
— 2.34  
— 2.30  
— 2.26  
— 2.22

— 1.17  
— 1.08




4h



S37


**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4h**

AM-85-P2-13C.3.fid — AM-85-P2-13C



S38

# HRMS spectrum of compound 4h




<sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4i

AM-03-32-2-1H.1.fid — AM-03-32-2-1H


8.10  
8.10  
8.08  
8.08  
7.65  
7.63  
7.63  
7.62  
7.61  
7.61  
7.43  
7.43  
7.41  
7.41  
7.37  
7.37  
7.35  
7.34  
7.33  
7.30  
7.30  
7.28  
7.28  
7.26  
7.06  
7.04  
5.13

2.62  
2.61  
2.28  
2.26  
2.24

1.15  
1.08



4i




S40




$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4i

AM-03-32-13C.1.fid — AM-03-32-13C




S41

# HRMS spectrum of compound 4i




<sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4j

AM-94-P3-1H.1.fid — AM-94-P3-1H




**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4j**

AM-94-P3-13C.1.fid — AM-94-P3-13C




### HRMS spectrum of compound 4j




# <sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4k

AM-68-P2-1H.1.fid — AM-68-P2-1H




**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4k**

AM-68-P2-13C.3.fid — AM-68-P2-13C




# HRMS spectrum of compound 4k






# <sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4I

AM-03-67-P2-1H.1.fid — AM-03-67-P2-1H




4I




**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4l**

AM-03-67-P2-13C.1.fid — AM-03-67-P2-13C



# HRMS spectrum of compound 4l



**<sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4m**


ATK-AM-03-39-1H.1.fid — ATK-AM-03-39-1H

8.04  
8.03  
7.58  
7.57  
7.56  
7.55  
7.38  
7.36  
7.28  
7.26  
7.06  
7.04


— 5.11

2.61  
2.61  
2.28  
2.26  
2.24

1.15  
1.08




**4m**




**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4m**

ATK-AM-03-39-13C.1.fid — ATK-AM-03-39-13C



S53

### HRMS spectrum of compound 4m




# <sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4n

AM-03-70-1H.1.fid — AM-03-70-1H


7.96  
7.96  
7.81  
7.79  
7.58  
7.57  
7.55  
7.55  
7.46  
7.45  
7.44  
7.39  
7.37  
7.30  
7.30  
7.28  
7.28  
7.26  
5.90

2.63  
2.32  
2.28  
2.22  
2.18

1.14  
1.05




4n




**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4n**

AM-03-70-13C.1.fid — AM-03-70-13C





### HRMS spectrum of compound 4n



# <sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4o


AM-03-69-P2-1H.21.fid — AM-03-69-P2-1H

8.12  
8.11  
8.02  
7.61  
7.60  
7.60  
7.58  
7.56  
7.42  
7.41  
7.26


5.22

2.65  
2.34  
2.30  
2.26  
2.23

1.17  
1.08




4o




**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4o**

AM-03-69-P2-13C.23.fid — AM-03-69-P2-13C



# HRMS spectrum of compound 4o



<sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4p

AM-95-P2-1H.3.fid — AM-95-P2-1H


8.01  
8.01  
7.81  
7.77  
7.76  
7.74  
7.73  
7.72  
7.56  
7.55  
7.40  
7.38  
7.37  
7.37  
7.26

— 5.31


2.66  
2.65  
2.31  
2.28  
2.24  
2.21

— 1.63

1.16  
1.07




4p




$^{13}\text{C} \{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4p

AM-95-P2-13C.1.fid — AM-95-P2-13C



### HRMS spectrum of compound 4p



**<sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4q**


AM-43-P2C-1H.1.fid — AM-43-P2C-1H

8.20  
8.20  
7.72  
7.72  
7.70  
7.69  
7.32  
7.30  
7.28  
7.26  
7.26  
7.05  
7.03


— 5.11

2.61  
2.61  
2.28  
2.26  
2.24

1.15  
1.08




**4q**






**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4q**

AM-43-P2-13C.3.fid — AM-43-P2-13C




### HRMS spectrum of compound 4q




<sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4r

AM-03-73-P2-1H.1.fid — AM-03-73-P2-1H




**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4r**

AM-03-73-P2-13C.3.fid — AM-03-73-P2-13C




### HRMS spectrum of compound 4r





# <sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4s

ATK-AM-03-51-1H.1.fid — ATK-AM-03-51-1H




**$^{13}\text{C}$  { $^1\text{H}$ } NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4s**

ATK-AM-03-51-13C.1.fid — ATK-AM-03-51-13C



**4s**

# HRMS spectrum of compound 4s







**<sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4t**

ATK-AM-03-47-1H.1.fid — ATK-AM-03-47-1H

8.20  
8.20  
7.72  
7.72  
7.70  
7.70  
7.40  
7.39  
7.39  
7.38  
7.37  
7.37  
7.33  
7.31  
7.26  
7.24  
7.23  
7.22  
7.15  
7.14  
— 5.15  
— 2.62  
2.28  
2.26  
— 1.15  
— 1.08




**4t**




**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4t**

ATK-AM-03-47-13C.7.fid — ATK-AM-03-47-13C




S74

# HRMS spectrum of compound 4t




**<sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4u**

ATK-AM-48-1H.1.fid — ATK-AM-48-1H



**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4u**




ATK-AM-48-13C.3.fid — ATK-AM-48-13C




S77

**$^{19}\text{F}$  NMR (471 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4u**


AM-03-48-19F.1.fid — AM-03-48-19F



**4u**



### HRMS spectrum of compound 4u



<sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4v


AM-03-45-D2-1H.1.fid — AM-03-45-D2-1H

8.20  
8.19  
7.74  
7.73  
7.72  
7.71  
7.37  
7.37  
7.36  
7.35  
7.35  
7.34  
7.32  
7.28  
7.28  
7.27  
7.26  
7.25


5.09

2.62  
2.32  
2.28  
2.26  
2.22

1.15  
1.08




4v






**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4v**

AM-03-45-D1-13C.5.fid — AM-03-45-D1-13C




### HRMS spectrum of compound 4v




<sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4w

AM-03-87-1H.5.fid — AM-03-87-1H





**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4w**

AM-03-87-13C.1.fid — AM-03-87-13C




**$^{19}\text{F}$  NMR (471 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4w**


AM-03-87-19F.1.fid — AM-03-87-19F



**4w**



### HRMS spectrum of compound 4w




# <sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4x

AM-79-P2-1H.1.fid — AM-79-P2-1H


7.74  
7.73  
7.72  
7.71  
7.45  
7.44  
7.42  
7.41  
7.40  
7.38  
7.38  
7.37  
7.36  
7.35  
7.35  
7.33  
7.32  
7.26  
7.25  
7.23  
7.16  
7.14  
7.12  
5.15

2.62  
2.32  
2.28  
2.26  
2.22

1.15  
1.08




4x



**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4x**



AM-03-79-P2-13C.10.fid — AM-03-79-P2-13C






<sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>) spectrum of compound 4x


AM-03-79-19F.1.fid — AM-03-79-19F



4x



# HRMS spectrum of compound 4x



<sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4y


AM-64-P2-1H.1.fid — AM-64-P2-1H

7.86  
7.86  
7.43  
7.43  
7.41  
7.40  
7.31  
7.29  
7.28  
7.27  
7.26  
7.04  
7.02


5.12

2.61  
2.38  
2.27  
2.25  
2.23

1.14  
1.08




4y




**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4y**

AM-64-P2-13C.1.fid — AM-64-P2-13C



S92

# HRMS spectrum of compound 4y



# <sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4z

AM-66-P2-1H.1.fid — AM-66-P2-1H


7.86  
7.85  
7.45  
7.45  
7.44  
7.43  
7.36  
7.35  
7.35  
7.34  
7.34  
7.33  
7.31  
7.29  
7.28  
7.27  
7.27  
7.26

5.11


2.61  
2.39  
2.31  
2.28  
2.25  
2.22

1.64

1.15  
1.07




4z




<sup>13</sup>C {<sup>1</sup>H} NMR (125 MHz, CDCl<sub>3</sub>) spectrum of compound 4z

AM-66-P2-13C.3.fid — AM-66-P2-13C



# HRMS spectrum of compound 4z






# <sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4aa

AM-03-100-1H.1.fid — AM-03-100-1H


7.87  
7.86  
7.46  
7.46  
7.44  
7.43  
7.39  
7.38  
7.38  
7.37  
7.37  
7.36  
7.34  
7.32  
7.29  
7.28  
7.28  
7.26  
7.19  
7.17  
7.15  
7.11  
7.11  
7.09  
7.09  
5.13

2.63  
2.62  
2.28  
2.27

1.15  
1.09




4aa




**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4aa**

AM-03-100-P2-13C.5.fid — AM-03-100-P2-13C



4aa

### HRMS spectrum of compound 4aa



# <sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>) spectrum of compound 4ab


AM-03-86-1H.2.fid — AM-03-86-1H

7.48  
7.47  
7.41  
7.41  
7.39  
7.39  
7.35  
7.35  
7.33  
7.26  
7.25  
7.24  
7.22  
7.21  
7.21  
7.20  
7.19  
7.14  
7.12  
7.11  
5.16


3.85  
3.81

2.62  
2.62  
2.61  
2.31  
2.28  
2.26  
2.23

1.15  
1.08




4ab




**$^{13}\text{C}$   $\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of compound 4ab**


AM-03-86-13C.4.fid — AM-03-86-13C




### HRMS spectrum of compound 4ab



### HRMS spectrum of intermediate B



# HRMS spectrum of intermediate D







## References

- 1 D. S. Chandrashekar, S. K. Karthikeyan, P. K. Korla, H. Patel, A. R. Shovon, M. Athar, G. J. Netto, Z. S. Qin, S. Kumar, U. Manne, C. J. Creighton and S. Varambally, *Neoplasia*, 2022, **25**, 18–27.
- 2 O. Trott and A. J. Olson, *J Comput Chem*, 2010, **31**, 455–461.
- 3 T. Mosmann, *Journal of Immunological Methods*, 1983, **65**, 55–63.
- 4 D. Wu and P. Yotnda, *JoVE*, 2011, 3357.